Introduction/Overview
Ganoderma lucidum（Ganoderma lucidum）As a treasure of traditional Chinese medicine, it has a medicinal history of over two thousand years and is known as the "immortal herb". Modern pharmacological research has revealed that many biological activities of Ganoderma lucidum are closely related to the triterpenoid compounds it is rich in, among which ganoderic acid components are particularly crucial. Ganoderic acid F (GA-F, CAS number: 98665-15-7) is an important member of the ganoderic acid family and has attracted much attention due to its significant anti-tumor and anti metastatic activities. In recent years, with the development of molecular biology and high-throughput screening techniques, researchers' understanding of GA-F has deepened from macroscopic pharmacological observations to microscopic molecular mechanisms. Research has shown that GA-F not only exerts anti-tumor effects directly by inhibiting angiogenesis, inducing tumor cell apoptosis and autophagy, but also demonstrates complex and sophisticated regulatory capabilities in the field of immune regulation, involving multiple key signaling pathways such as TLR4, STAT3, NF - κ B. This article aims to systematically review the chemical characteristics, pharmacological activity, mechanism of action, and pharmacological research progress of Ganoderma lucidum acid F, in order to provide comprehensive scientific reference for the deep development and clinical application of this natural product.
Chemical structure and physicochemical properties
Lingzhi acid F belongs to highly oxidized lanostane type tetracyclic triterpenoids. Its molecular formula is C30H42O9 and its molecular weight is 570.6790. Its core structure is the steroid mother nucleus, which undergoes hydroxylation or carbonylation at multiple positions such as C-3, C-7, C-15, C-22, C-23, and C-26 is usually present in the form of carboxyl groups. These oxygen-containing functional groups are important structural foundations for its biological activity and also determine its strong polarity.
From the analysis of physical and chemical properties, the lipid water partition coefficient (LogP) of ganoderic acid F is 2.8643, indicating that it has a certain lipophilicity, but not high lipid solubility. Its topological polar surface area (TPSA) is as high as 148.9500 Å ², mainly attributed to the presence of multiple hydroxyl and carboxyl groups in the molecule, which makes the molecular polarity strong. The calculated water solubility is relatively low, about 0.0105 mg/mL, which is consistent with the nature of its triterpenoid compounds, suggesting that solubilization strategies may need to be considered in formulation development. Preliminary predictions of drug efficacy indicate that its ability to cross the blood-brain barrier is relatively low, which to some extent limits its direct effects on central nervous system related diseases, but may also reduce potential neurotoxic risks. In addition, the hERG inhibition risk prediction was negative, and the Ames test predicted a value of 0.0, indicating a low risk of cardiac and genetic toxicity, providing favorable early data for its safety evaluation.
Plant sources and extraction methods
Lingzhi acid F mainly comes from fungi of the Ganoderma genus in the family Polyporus, including Ganoderma lucidum（Ganoderma lucidum）And Zizhi（Ganoderma sinense）As the main source. It is distributed in fruiting bodies, mycelium, and spore powder, but its content is significantly affected by factors such as bacterial strain, growth environment, cultivation conditions, harvesting period, and location.
At present, the extraction of ganoderic acid F mainly relies on organic solvent extraction method. Common solvents include methanol, ethanol, ethyl acetate, chloroform, etc. Among them, ethanol is often used as the preferred solvent due to its low toxicity, high extraction efficiency, and environmental friendliness. The typical extraction process is to heat reflux or ultrasound assisted extraction of dried and crushed Ganoderma lucidum fruiting bodies or mycelium with appropriate concentration of ethanol (such as 75% -95%), followed by filtration and concentration to obtain crude extract. Due to the coexistence of ganoderic acid F with other structurally similar ganoderic acids in the crude extract, separation and purification are key steps in obtaining high-purity monomers. Conventional purification techniques include:
1. Liquid-liquid extraction Using water and organic phases with different pH values (such as ethyl acetate) for distribution, to preliminarily enrich acidic triterpenoids.
2. column chromatography This is the core purification method, often using silica gel column chromatography with different ratios of petroleum ether ethyl acetate or chloroform methanol gradient elution. Reversed silica gel (such as C18), macroporous adsorption resin and Sephadex gel (LH-20) column chromatography are also widely used for further refining.
3. recrystallization Recrystallizing the enriched fraction in a suitable solvent system (such as methanol water or acetone water) can obtain high-purity ganoderic acid F crystals.
In recent years, some new technologies such as high-speed countercurrent chromatography (HSCCC) and preparative high-performance liquid chromatography (Prep HPLC) have become important tools for obtaining high-purity ganoderic acid F standards due to their high separation efficiency and high degree of automation. In addition, optimizing the liquid fermentation conditions of Ganoderma lucidum (such as carbon and nitrogen sources, pH, inducer addition, etc.) to increase the yield of GA-F in mycelium is also a current research hotspot in biomanufacturing.
Pharmacological activity research
Numerous in vitro and in vivo pharmacological studies have confirmed that ganoderic acid F has broad and significant biological activities, with its core pharmacological effects concentrated in the fields of anti-tumor and immune regulation.
1. Anti tumor and anti metastatic activity
This is the most notable pharmacological effect of Ganoderma lucidum acid F. Research shows that GA-F has growth inhibitory activity on a variety of human tumor cell lines, including liver cancer, lung cancer, breast cancer, colon cancer, prostate cancer, etc. Its anti-tumor effect has the characteristics of multiple pathways and targets:
- Inhibit cell proliferation Inhibiting abnormal proliferation of tumor cells by blocking the cell cycle (commonly in G1 or G2/M phase).
- Inducing cell death It can activate the mitochondrial apoptosis pathway (such as regulating the Bcl-2/Bax ratio and activating Caspase-3/9), inducing programmed cell death in tumor cells. In addition, research suggests that it may affect the autophagy flow of tumor cells by regulating the levels of autophagy related proteins such as LC3-II and p62.
- Inhibit tumor invasion and metastasis This is a prominent feature of GA-F. It can significantly downregulate the expression and activity of matrix metalloproteinases (such as MMP-2, MMP-9), thereby inhibiting the degradation and invasion of extracellular matrix by tumor cells. At the same time, it can also inhibit the expression and secretion of vascular endothelial growth factor (VEGF), block tumor angiogenesis, cut off tumor nutrition supply and metastasis channels.
- Reverse multidrug resistance Preliminary studies have shown that GA-F may enhance the accumulation of certain chemotherapy drugs in drug-resistant tumor cells by inhibiting the function or expression of P-glycoprotein (P-gp), thereby playing a role in chemotherapy sensitization.
2. Immune regulatory activity
Lingzhi acid F exhibits a bidirectional regulatory effect on the immune system, which has been explained by modern science in the traditional concept of "strengthening the body and consolidating the foundation".
- Immune enhancement effect Under immunosuppressive conditions, GA-F can promote the activity of immune cells. For example, it can stimulate the phagocytic function of macrophages, promote the proliferation and activation of T lymphocytes and natural killer cells (NK cells), and upregulate the production of related cytokines (such as IL-2, IFN - γ).
- Immunosuppressive effect In models of excessive immune activation or autoimmune diseases, GA-F exhibits anti-inflammatory and immunosuppressive properties. It can inhibit the excessive release of pro-inflammatory factors such as TNF - α, IL-6, IL-1 β, and may promote the production of anti-inflammatory factor IL-10, thereby regulating immune balance.
3. Other activities
The study also found that ganoderic acid F has antioxidant stress (clearing free radicals, enhancing antioxidant enzyme activity), liver protection (combating chemical liver injury), regulation of calcium homeostasis, and alleviation of endoplasmic reticulum stress. These activities are closely related to its anti-tumor and cell protective effects.
Mechanism of action and molecular targets
The multiple pharmacological activities of Ganoderma lucidum acid F stem from its precise intervention in the complex intracellular signaling network. Significant progress has been made in the study of its mechanism of action and molecular targets, especially in the context of immune regulatory pathways.
Core signaling pathway and target network:
1. TLR4/NF - κ B pathway Toll like receptor 4 (TLR4) is a key molecule that connects innate and acquired immunity. GA-F has been shown to inhibit the overactivation of TLR4, thereby blocking the nuclear translocation of its downstream nuclear factor kappa B (NF - κ B, encoded by the NFKB1 gene). NF - κ B is a core transcription factor that regulates the expression of inflammatory factors (TNF - α, IL-6), chemokines, and cell survival proteins. By inhibiting this pathway, GA-F can effectively alleviate inflammatory responses and suppress chronic inflammation associated with tumor progression in the tumor microenvironment.
2. JAK/STAT pathway The signal transduction and transcription activator (STAT) family, especially STAT3, plays a crucial role in tumor cell proliferation, survival, and immune escape. GA-F can inhibit the phosphorylation activation of STAT3 by JAK kinase, inhibit the entry of STAT3 dimer into the nucleus, and thus downregulate the expression of its target genes (such as Bcl-2, Cyclin D1, VEGF). Meanwhile, its regulation of STAT4 may affect the differentiation of Th1 cells. In addition, GA-F can also affect STAT5 signaling triggered by cytokines such as IL-2, regulating T cell proliferation.
3. TGF - β/Smad pathway Transforming growth factor - β 1 (TGFB1) plays a dual role. GA-F may inhibit tumor growth in the early stages and affect the function of regulatory T cells (Tregs) in immune regulation by regulating this pathway. The expression of the key transcription factor FOXP3 in Treg cells is also regulated by various signaling pathways, including TGF - β, and GA-F may indirectly affect the expression of FOXP3, thereby regulating immune tolerance.
4. Immune checkpoint molecules Research suggests that GA-F may downregulate the expression or function of immune checkpoint molecules such as cytotoxic T lymphocyte associated antigen 4 (CTLA4), thereby relieving inhibition of effector T cells and enhancing anti-tumor immune response.
5. Cytokine network balance GA-F can regulate the balance between Th1/Th2/Th17/Treg cell subsets. It usually manifests as promoting Th1 type response (increasing IFN - γ and IL-2 production), while inhibiting excessive Th2 type response and Th17 type response, and may affect Treg cells by regulating IL-10 and TGF - β, ultimately tilting the immune status towards anti-tumor and anti autoimmune directions.
Integration mechanism view:
In the tumor model, ganoderic acid F forms a synergistic network through the multi-target action mentioned above: on the one hand, it directly induces tumor cell apoptosis and inhibits proliferation (through STAT3, etc.); On the other hand, by inhibiting the inflammatory microenvironment mediated by NF - κ B, downregulating VEGF to resist angiogenesis, and regulating immune cell function (such as enhancing effector T and NK cell activity, regulating Treg function), the tumor immune microenvironment is reshaped, indirectly exerting anti-tumor and anti metastatic effects. Its role in combating oxidative stress and alleviating endoplasmic reticulum stress provides another layer of mechanism explanation for its cell protective effect and adjuvant anti-tumor effect.
Evaluation of drug properties and pharmacokinetics
Although the pharmacological activity of ganoderic acid F is clear, its conversion from lead compounds to drugs still faces challenges in drug formation, and related pharmacokinetic studies are gradually deepening.
Drug analysis:
Based on its physicochemical parameters, ganoderic acid F belongs to Class IV (low solubility, low permeability) compounds in the Biopharmaceutical Classification System (BCS). Its high TPSA and molecular weight may limit its passive transmembrane diffusion. Although the LogP value shows some lipophilicity, the presence of carboxyl groups may partially ionize it at physiological pH, further affecting its membrane permeability. Low water solubility and low blood-brain barrier permeability are its main pharmaceutical defects. Therefore, formulation strategies are crucial for improving its bioavailability, such as making nanocrystals, liposomes, micelles, or prodrugs.
Progress in pharmacokinetic research:
Existing animal pharmacokinetic studies (mainly conducted in rat models) have shown that oral absorption of ganoderic acid F is poor and its absolute bioavailability is low. It is widely distributed in the body, but difficult to enter the central nervous system. Metabolic studies have shown that ganoderic acid F undergoes extensive phase I metabolism (such as hydroxylation and carbonyl reduction) and phase II binding reactions (such as glucuronidation) in the liver, and its prototype drug is eliminated quickly in plasma with a short half-life. The main excretion pathway may be fecal excretion (including unabsorbed prototype drugs and bile excreted metabolites), followed by urinary excretion. These features suggest that developing suitable drug delivery systems and dosage forms (such as enteric coated formulations, intravenous nano formulations) to increase their systemic exposure and duration of action is a key focus of future research.
Clinical application prospects and prospects
Lingzhi acid F, as a multi-target and multifunctional natural product lead compound, has broad prospects for clinical application development, but there are also clear challenges.
Potential application directions:
1. Antitumor adjuvant therapy drugs As an adjuvant drug for chemotherapy, radiotherapy, or immunotherapy, utilizing its anti metastasis, anti angiogenesis, immune regulation, and possible sensitization effects can improve overall efficacy, alleviate side effects, and enhance patients' quality of life.
2. Therapeutic agents for immune related diseases Based on its bidirectional immune regulatory properties, it can be used to treat autoimmune diseases (such as rheumatoid arthritis, inflammatory bowel disease) or excessive inflammatory reactions (such as sepsis), as well as for immune reconstruction in immunosuppressed patients (such as after chemotherapy).
3. Liver protectants Develop drugs or health products for the prevention and treatment of chemical liver injury, fatty liver, or liver fibrosis.
Challenges and Future Prospects:
1. Source and Supply Extracting and separating from natural Ganoderma lucidum has high cost and low yield. In the future, it is necessary to vigorously develop high-yield GA-F Ganoderma strains, optimize fermentation processes, or explore synthetic biology pathways (such as yeast cell factories) for green biosynthesis.
2. Optimization of drug properties To address the bottleneck of poor solubility and permeability, it is necessary to strengthen research on new formulation technologies. The synthesis of derivatives or prodrugs through structural modification is also a classic strategy for improving their pharmacokinetic properties.
3. Deep exploration of mechanisms At present, the understanding of the mechanism of action of GA-F is still fragmented, especially its specific timing and network integration mechanism on different immune cell subsets in the immune microenvironment need to be elucidated. The use of proteomics, chemical proteomics and other technologies to identify its direct targets will greatly promote mechanism research.
4. Preclinical and clinical research It is urgent to carry out systematic and standardized GLP toxicology evaluation and more in-depth pharmacokinetic studies to provide complete data for clinical trial application. Exploring its combination therapy and synergistic mechanism with existing standard therapies is a practical path to promote its clinical application.
Conclusion
Lingzhi acid F, as a representative bioactive triterpenoid in Ganoderma lucidum, has become a star molecule in the field of natural product drug development due to its unique anti-tumor, anti metastasis, and bidirectional immune regulation multiple pharmacological effects. From chemical structure to pharmacological activity, from multi-target mechanism of action to preliminary pharmacological evaluation, research has drawn a promising application blueprint for it. However, its inherent physicochemical property defects and complex in vivo metabolic processes constitute the main barriers to its transformation into innovative drugs. Future research should focus on the strategy of interdisciplinary integration - combining synthetic biology to ensure supply, optimizing drug chemistry structures, improving delivery efficiency with new formulation technologies, and elucidating integration mechanisms through systems biology - to jointly promote the transition of ganoderic acid F from the laboratory to clinical practice, ultimately providing a new treatment option based on traditional and modern science for the prevention and treatment of tumors and immune diseases.
